Altogether, these results suggest that post-transcriptional mechanisms such as rRNA processing might provide new targets in AML and be explored in future personalized patient profiling to determine sensitivities to relevant pathway inhibitors, possibly including inhibition of eIF4A3 itself. Here, EIF4A3 is linked to acute myeloid leukemia.